10-K: CVRx Reports 10% Revenue Growth, Expands Heart Failure Market

CVRx, Inc. reported a 10% increase in revenue to $56.7 million for fiscal year 2025, driven by U.S. sales growth and expanded market opportunities for its Barostim therapy.

Summary

• Revenue increased by 10% to $56.7 million for the year ended December 31, 2025, compared to $51.3 million in 2024.
• Net loss improved by 11% to $53.3 million in 2025, down from $60.0 million in 2024.
• Gross margin increased to 85% in 2025 from 84% in 2024, primarily due to an increase in the average selling price and manufacturing efficiencies.
• U.S. revenue grew 10% to $51.9 million in 2025, with 1,648 units sold, up from 1,522 units in 2024.
• European revenue increased 16% to $4.8 million in 2025, with 219 units sold, up from 204 units in 2024.
• Active implanting centers in the U.S. increased to 252 as of December 31, 2025, from 223 in 2024.
• U.S. sales territories expanded to 53 as of December 31, 2025, from 48 in 2024.
• Research and development expenses remained stable at $11.1 million for both 2025 and 2024.
• Selling, general and administrative expenses decreased by 3% to $88.5 million in 2025, largely due to a $7.9 million decrease in non-cash stock-based compensation.
• Cash and cash equivalents were $75.7 million as of December 31, 2025, down from $105.9 million in 2024.
• Net cash used in operating activities increased to $40.2 million in 2025 from $39.1 million in 2024.
• The company initiated the BENEFIT-HF pivotal trial in January 2026 to evaluate Barostim's impact on all-cause mortality and heart failure decompensation in an expanded patient population, with expected enrollment of 2,500 patients across 150 centers over five years.
• A successful BENEFIT-HF trial could expand the U.S. prevalence-based market opportunity from an estimated $10.5 billion (339,000 patients) to $30.5 billion (983,000 patients).
• New Category I CPT codes for Barostim implant and follow-up services became effective January 1, 2026, expected to improve prior authorization predictability and eliminate automatic denials.
• The Loan Agreement with Innovatus was amended on January 9, 2026, increasing available term loans by $50.0 million to an aggregate of $100.0 million and extending the maturity date to 2031; an additional $10.0 million was borrowed.
• A new Open Market Sale Agreement was entered into on January 12, 2026, for an at-the-market (ATM) offering of common stock up to $50.0 million.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, demonstrating solid revenue growth and improved net loss, coupled with strategic moves to expand market opportunity and secure additional financing. The clinical data for Barostim remains strong, and regulatory advancements are favorable, though continued losses and competitive pressures warrant a balanced perspective.

Positives

• Revenue increased by 10% to $56.7 million in 2025, demonstrating continued commercial growth.
• Net loss improved by 11% to $53.3 million in 2025, indicating progress towards profitability.
• Gross margin increased to 85% in 2025, driven by manufacturing efficiencies and a higher average selling price.
• Significant expansion of U.S. active implanting centers (252 in 2025 vs. 223 in 2024) and sales territories (53 in 2025 vs. 48 in 2024).
• Initiation of the BENEFIT-HF pivotal trial has the potential to nearly triple the estimated U.S. market opportunity for Barostim to $30.5 billion.
• New Category I CPT codes for Medicare reimbursement, effective January 2026, are expected to improve access and predictability for Barostim procedures.
• FDA approved expanded labeling for Barostim in December 2023, simplifying indications and including comprehensive clinical data.
• The BeAT-HF pivotal trial demonstrated compelling safety (97% MANCE-free rate) and effectiveness, with sustained improvements in exercise capacity, quality of life, and NYHA functional status.
• Barostim therapy showed a directionally favorable 34% reduction in all-cause death, LVAD, or heart transplant in the Barostim group.
• The minimally invasive implant procedure for Barostim allows for quick patient recovery and typically an outpatient setting.
• A company-sponsored analysis predicted Barostim Therapy could become a lower-cost alternative treatment within three years, resulting in significant healthcare cost savings.
• The device offers inherent patient compliance and durability with a 5-6 year battery life that does not require recharging.
• The company secured an additional $50.0 million in available term loans, increasing the total facility to $100.0 million, and entered into a new $50.0 million ATM offering, strengthening capital resources.

Negatives

• The company continues to incur significant net losses ($53.3 million in 2025) and expects this trend to continue for the foreseeable future.
• An accumulated deficit of $590.7 million as of December 31, 2025, highlights a history of substantial losses.
• Net cash used in operating activities increased to $40.2 million in 2025, indicating continued cash burn from operations.
• The post-market phase effectiveness primary endpoint of cardiovascular mortality and heart failure hospitalization was not met in the BeAT-HF pivotal trial.
• The company is highly dependent on a single product, Barostim, making it vulnerable to market acceptance issues or product-related problems.
• Significant competition exists from larger, well-established medical device companies with substantially greater resources.
• Reliance on a limited number of third-party suppliers for critical components creates vulnerability to supply shortages and disruptions.
• Operating at a single manufacturing facility in Minneapolis poses a risk of significant disruption from natural disasters or other events.
• The company has limited commercial sales experience and faces challenges in recruiting and retaining qualified sales personnel.
• Seasonally lower rates of implants are observed in the first fiscal quarter, which can impact revenue predictability.
• The company's ability to use its net operating losses and tax credits to offset future taxable income may be subject to limitations.

Risks

• We have a history of significant losses, which we expect to continue, and we may not be able to achieve or sustain profitability.
• Our principal stockholders, management and directors (one of whom is affiliated with one of our principal stockholders) own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.
• We have a limited history operating as a commercial company and are highly dependent on a single product, Barostim, and the failure to increase market acceptance in the U.S. for Barostim would negatively impact our business, liquidity, and results of operations.
• We have limited commercial sales experience marketing and selling Barostim, and if we are unable to continue to maintain and grow sales and marketing capabilities, we will be unable to generate sustained and increasing product revenue.
• We must continue to demonstrate to physicians and patients the merits of Barostim.
• If third-party payers do not provide adequate coverage and reimbursement for the use of Barostim, our revenue will be negatively impacted.
• Our industry is highly competitive; if our competitors, many of which are large, well-established companies with substantially greater resources than us and have a long history of competing in the heart failure market, are better able to develop and market products that are safer, more effective, less costly, easier to use, or otherwise more attractive than Barostim, our business will be adversely impacted.
• If we fail to receive access to hospitals, our sales may decrease.
• We are dependent upon third-party manufacturers and suppliers, and in some cases a limited number of suppliers, making us vulnerable to supply shortages, loss or degradation in performance of the suppliers, price fluctuations, and ongoing supply chain disruptions, which could harm our business.
• Manufacturing risks may adversely affect our ability to manufacture our product and could reduce our gross margin and profitability.
• Our clinical studies may not produce results necessary to support regulatory clearance or approval, and could produce negative or inconclusive results.
• A pandemic, epidemic or outbreak of an infectious disease in the U.S. or worldwide could adversely affect our business.
• We may face product liability claims that could be costly, divert management's attention and harm our reputation.
• We may in the future become involved in lawsuits to protect or enforce our intellectual property or defend ourselves against intellectual property disputes, which could be expensive, time consuming and ultimately unsuccessful, and could result in the diversion of significant resources, thereby hindering our ability to effectively commercialize our existing or future products.
• If we fail to retain our key executives or recruit and hire new employees, our operations and financial results may be adversely affected while we attract other highly qualified personnel.
• We will continue to obtain long-term clinical data regarding the safety and effectiveness of our products, which could impact future adoption and regulatory approvals.
• Failure to protect our information technology infrastructure against cyber-based attacks, network security breaches, service interruptions, or data corruption could significantly disrupt our operations and adversely affect our business and operating results.
• If important assumptions about the potential market for our product are inaccurate, or if we have failed to understand what people with HF are seeking in a treatment, we may not be able to increase our revenue or achieve profitability.
• Unfavorable economic conditions could adversely affect our business, financial condition, or results of operations.
• We may enter into strategic collaborations, in-licensing arrangements, or alliances with third parties that may not result in the development of commercially viable products or the generation of significant future revenue.
• We may seek to grow our business through acquisitions of complementary products or technologies, and the failure to manage acquisitions, or the failure to integrate them with our existing business, could impair our ability to execute our business strategies.
• The constant growth and development of technology, including the increased use of Artificial Intelligence (AI), present risks and challenges to our operations and the use of our products that could give rise to legal or regulatory action, damage our reputation or otherwise materially harm of our business.
• Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our existing and future products.
• We may not be able to adequately protect our intellectual property rights throughout the world.
• We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of our competitors or are in breach of non-disclosure or confidentiality agreements with our competitors.
• If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
• If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed.
• We may be required to obtain additional funds in the future, and these funds may not be available on acceptable terms or at all.
• Our operating results may vary significantly annually or from quarter to quarter, which may negatively impact our stock price in the future.
• We are required to maintain high levels of inventory, which could consume a significant amount of our resources, reduce our cash flows and lead to inventory impairment charges.
• The seasonality of our business creates variance in our quarterly revenue, which makes it difficult to compare or forecast our financial results.
• We are subject to risks associated with currency fluctuations, and changes in foreign currency exchange rates could impact our results of operations.
• Our ability to use our net operating losses and tax credits to offset future taxable income and taxes may be subject to certain limitations, and we may not be able to utilize a significant portion of our net operating loss and tax credit carryforwards prior to their expiration.
• We are subject to complex tax rules, and any audits, investigations or tax proceedings could have a material adverse effect on our business, results of operations, and financial condition.
• Changes in U.S. and non-U.S. tax laws could adversely affect our financial condition and results of operations.
• Barostim is subject to extensive governmental regulation, and our failure to comply with applicable requirements could cause our business to suffer.
• The misuse or off-label use of our product may harm our image in the marketplace, result in injuries that lead to product liability suits, which could be costly to our business, or result in costly investigations and sanctions from the FDA and other regulatory bodies if we are deemed to have engaged in inappropriate promotion.
• The discovery of serious safety issues with Barostim, or a recall of Barostim either voluntarily or at the direction of the FDA or another governmental authority, could harm our reputation, business, and financial results.
• Our products may cause or contribute to adverse medical events or be subject to failures or malfunctions that we are required to report to the FDA and European regulators, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition, and results of operations.
• We are subject to certain federal, state, and foreign fraud and abuse laws, transparency and privacy and security laws and regulations, which, if violated, could subject us to substantial penalties.
• Healthcare legislative reform measures may have a material adverse effect on us.
• We expect that the price of our common stock will fluctuate substantially, and you may not be able to resell shares of our common stock at or above the price you paid.
• Securities analysts may not publish favorable research or reports about our business or may publish no information at all, which could cause our stock price and trading volume to decline.
• We are an emerging growth company, and as a result of the reduced disclosure and governance requirements applicable to emerging growth companies, our common stock may be less attractive to investors.
• Because we have opted to take advantage of the JOBS Act provision which allows us to delay implementing new accounting standards, our financial statements may not be directly comparable to other public companies.
• If we are unable to maintain effective internal control over financial reporting in the future, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could be adversely affected.
• Our principal stockholders, management, and directors (one of whom is affiliated with one of our principal stockholders) own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.
• Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.
• Anti-takeover provisions included in our amended and restated certificate of incorporation and amended and restated bylaws, as well as under Delaware law, could discourage a takeover.
• We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.

Future Outlook

The company expects continued revenue growth driven by expanding its U.S. commercial sales force, increasing awareness of Barostim, and seeking expanded labeling for new indications. A new pivotal trial (BENEFIT-HF) is underway, which, if successful, could nearly triple the estimated U.S. market opportunity for Barostim to $30.5 billion. Research and development will focus on technological advancements of Barostim and exploring its potential for other cardiovascular diseases like hypertension and arrhythmias, requiring additional FDA approvals and clinical trials. The company anticipates continued net losses for the next several years, requiring potential additional funding through equity and debt financing.

Management Comments

• We expect to continue to incur significant sales and marketing, research and development, regulatory, and other expenses as we grow our U.S. commercial sales force and expand our marketing efforts to increase adoption of Barostim, add new features to Barostim, obtain regulatory clearances or approvals for our planned or future products and conduct clinical trials on our existing and planned or future products.
• We will need to continue to generate significant additional revenue in order to achieve and sustain profitability.
• We believe that our existing cash, cash equivalents, short-term investments and revenue will be sufficient to meet our capital requirements and fund our operations for at least the next two years.
• We expect to continue to incur net losses for the next several years, which may require additional funding and could include future equity and debt financing.
• We believe that our component manufacturers are recognized in their field for their competency to manufacture the respective portions of Barostim and have quality systems established that meet FDA requirements.
• We seek to maintain higher levels of inventory to protect ourselves from supply interruptions and continue to seek to broaden and strengthen our supply chain through additional sourcing channels.
• We are committed to ongoing research and development efforts of Barostim with an emphasis on improving clinical outcomes, optimizing patient adoption and comfort, increasing access for a greater number of patients and enabling more physicians to perform the procedure.
• Our longer-term goal is to explore Barostim's potential to expand the indications for use to other cardiovascular diseases, including different forms of HF, hypertension, and arrhythmias.
• We consider our relationship with our employees to be good.
• Our mission is to team with clinicians to advance innovative device therapies that modulate the ANS to meaningfully improve the lives of people with chronic disease. We envision Barostim becoming a standard of care for the treatment of HF, accessible to all who would benefit.

Industry Context

StockSavvy.ai notes that CVRx operates in a highly competitive medical device industry, facing larger, well-established companies like Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, and Johnson & Johnson. The company's focus on neuromodulation for heart failure with reduced ejection fraction (HFrEF) addresses a significant unmet need, positioning Barostim as a unique device-based therapy. The transition to Category I CPT codes for Medicare reimbursement aligns with broader industry efforts to streamline access for innovative medical technologies, potentially accelerating adoption in a market where approximately 67% of the target patient population is Medicare-eligible. The ongoing BENEFIT-HF trial to expand indications reflects a common strategy in MedTech to broaden addressable markets and achieve economies of scale.

Comparison to Industry Standards

• Barostim's minimally invasive implant procedure (typically 1 hour, outpatient, two small skin incisions, no hardware in heart or vasculature) offers a less invasive alternative compared to other device-based treatments for HFrEF, such as Left Ventricular Assist Devices (LVADs) which require open-chest surgery and may destroy a portion of the heart, or Cardiac Contractility Modulation (CCM) which involves leads attached inside the heart's ventricles.
• The BeAT-HF pivotal trial demonstrated significant improvements in patient-centered outcomes, including a 56-meter increase in 6-Minute Hall Walk (6MHW) distance at six months (approximately twice the clinically meaningful 25-meter improvement) and a 14-point improvement in Minnesota Living with Heart Failure (MLWHF) quality of life score (greater than the clinically meaningful 5-point improvement). These results are robust compared to the symptomatic benefits typically seen with guideline-directed medical therapy alone.
• Barostim's safety profile, with a 97% major adverse neurological or cardiovascular system or procedure-related event (MANCE)-free rate, exceeded the pre-specified performance criteria of 85%, indicating a strong safety record for an implantable medical device.
• Unlike Cardiac Resynchronization Therapy (CRT), which is not eligible for approximately 59% of HFrEF patients with a narrow QRS complex, Barostim is indicated for a broader HFrEF patient population (NYHA Class III or II with recent Class III history, LVEF ≤ 35%, NT-proBNP < 1,600 pg/mL).
• The estimated potential U.S. market opportunity for Barostim, expanding from $10.5 billion to $30.5 billion with new indications, positions CVRx to address a substantial segment of the cardiovascular disease market, comparable to the large addressable markets targeted by leading medical device companies like Medtronic or Boston Scientific in their respective therapeutic areas.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.

Related Party Transactions

• The Loan and Security Agreement with Innovatus Life Sciences Fund I, LP, where Innovatus acts as collateral agent and a lender, represents a significant financial arrangement.
• Johnson & Johnson Innovation JJDC, Inc. previously held common stock warrants, which were exercised through a net exercise transaction for 604,000 shares of common stock during 2024.

Stakeholder Impact

• Shareholders: Experience potential for stock price volatility due to ongoing losses, dependence on a single product, and competitive pressures. Dilution risk from future equity raises is present, but there is also potential for long-term value appreciation if Barostim gains wider adoption and new indications are approved.
• Employees: Affected by management changes and the company's ability to attract and retain qualified personnel. Equity incentive plans and the Employee Stock Purchase Plan are in place to motivate and retain staff.
• Customers (Hospitals/Physicians): Benefit from Barostim's demonstrated clinical effectiveness and minimally invasive procedure. Improved Medicare reimbursement codes (Category I CPT) are expected to streamline billing and increase access to the therapy.
• Patients: Direct beneficiaries of Barostim Therapy for HFrEF, with documented improvements in exercise capacity, quality of life, and functional status. Expanded indications through ongoing trials could benefit a significantly larger patient population.
• Suppliers: The company's dependence on a limited number of suppliers for critical components creates a mutual risk, and the company is actively seeking to broaden its supply chain to mitigate this.
• Creditors: Innovatus Life Sciences Fund I, LP is a significant creditor with a $100.0 million loan facility. The company's ability to meet its debt obligations is tied to its future revenue growth and progress towards profitability.

Next Steps

• Continue to actively expand the direct sales force and commercial organization in the U.S.
• Continue to develop and expand upon the significant body of published clinical evidence that supports the safety and effectiveness of Barostim Therapy.
• Investigate the benefits of Barostim in an expanded population of patients with HF with mildly Reduced Ejection Fraction (HFmrEF) and HFrEF with NT-proBNP < 5,000 pg/mL in the large, multi-center, randomized controlled BENEFIT-HF trial.
• Analyze data from U.S. and European Union (EU) patient registries and other real-world evidence (RWE) datasets.
• Continue to invest in investigator-sponsored studies to further validate the mechanisms underlying Barostim's benefits.
• Focus near-term research and development efforts on the continued technological advancement of Barostim.
• Explore Barostim's potential to expand its indications for use to other cardiovascular diseases, including different forms of HF, hypertension, and arrhythmias, which would require additional FDA approvals and clinical trials.
• Monitor developments in CMS and private payer decisions regarding reimbursement and leverage the in-house market access team to obtain prior authorization approvals.
• Add new facilities as the company grows to accommodate expansion of operations.
• Complete enrollment for the BENEFIT-HF trial within five years, with a two-year follow-up period, resulting in an expected conclusion in five to seven years.
• Potentially seek additional funds through future equity and debt financing to satisfy liquidity requirements or accelerate growth strategies.

Key Dates

Recommendation

CVRx demonstrates promising revenue growth and an improving net loss, driven by strong U.S. sales and strategic market expansion efforts for Barostim. The initiation of the BENEFIT-HF trial and favorable Medicare reimbursement changes are significant positive catalysts for future growth. However, the company continues to incur substantial losses and relies heavily on a single product, facing intense competition and supply chain risks. The post-market effectiveness endpoint for CV mortality and HF hospitalization was not met, which is a notable concern. While the long-term market opportunity is substantial, the path to sustained profitability remains challenging and requires successful execution of its growth strategy and clinical trials. Therefore, a 'hold' recommendation is appropriate, acknowledging both the significant potential and the inherent risks.

Keywords

CVRx, Barostim, Heart Failure, HFrEF, Neuromodulation, Medical Device, FDA Approval, SEC Filing, 10-K, Financial Results, Clinical Trials, Market Opportunity, Reimbursement, Cardiovascular Disease, MedTech